Key facts
- This page summarizes Petter Veiby's Form 3 filing for Attovia Therapeutics, Inc. (ATTO).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2026, 19:36.
Petter Veiby - 04 Aug 2026 Form 3 Insider Report for Attovia Therapeutics, Inc. (ATTO)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- ATTO
- Reported as of
- 04 Aug 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Steven Chan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Petter Veiby filed Form 3 for Attovia Therapeutics, Inc. (ATTO) on 04 Aug 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002141655
Primary reporting owner
Veiby Petter
- Relationship
- Chief Scientific Officer
- Address
- C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS
- Signature
- /s/ Steven Chan, Attorney-in-Fact
- Signature date
- 04 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATTO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 104,951
- Date
- 04 Aug 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,382
- Exercise price
- $2.88
- Footnotes
- F1
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 107,642
- Exercise price
- $3.53
- Footnotes
- F2
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 89,343
- Exercise price
- $4.92
- Footnotes
- F3
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,837
- Exercise price
- $1.58
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on March 6, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
Footnote F2
The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 9, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
Footnote F3
The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 18, 2026, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
Footnote F4
The options vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on June 19, 2024, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.